Priced Oct 14, 2026 · range was $15–$17 · latest SEC filing Nov 16, 2026.
Pinch-zoom for details.
Clinical-stage drug developer that uses AI and its own technology to discover medicines; no products approved for sale.
Fiscal year
1st half
Fiscal year
1st half
Fiscal year
1st half
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Revenue | 1.19M | 9.43M | +689% | 3.93M | 12.8M | +225% |
| Operating result | (53.9M) | (82.3M) | −52.8% | (35.7M) | (53.5M) | −50.0% |
| Net result | (47.9M) | (77.3M) | −61.4% | (33.2M) | (50.1M) | −51.1% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | 1.19M | 9.43M | +689% |
| Operating result | (53.9M) | (82.3M) | −52.8% |
| Net result | (47.9M) | (77.3M) | −61.4% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Revenue | 3.93M | 12.8M | +225% |
| Operating result | (35.7M) | (53.5M) | −50.0% |
| Net result | (33.2M) | (50.1M) | −51.1% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing's own risk-factor headings, shortened.
The filing's own strategy headings, shortened.
Source: Iambic Therapeutics, Inc.'s Form 424B4, filed with the SEC on Oct 15, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back